Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

BACKGROUND: Doravirine is a novel, nonnucleoside reverse transcriptase inhibitor with demonstrated efficacy in treatment-naive adults with HIV-1. METHODS: In this open-label, active-controlled, noninferiority trial, adults with HIV-1 virologically suppressed for ≥6 months on 2 nucleoside reverse tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Margaret, Kumar, Princy, Molina, Jean-Michel, Rizzardini, Giuliano, Cahn, Pedro, Bickel, Markus, Mallolas, Josep, Zhou, Yan, Morais, Cristiana, Kumar, Sushma, Sklar, Peter, Hanna, George J., Hwang, Carey, Greaves, Wayne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2019
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905402/
https://www.ncbi.nlm.nih.gov/pubmed/30985556
http://dx.doi.org/10.1097/QAI.0000000000002056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905402/
https://www.ncbi.nlm.nih.gov/pubmed/30985556
http://dx.doi.org/10.1097/QAI.0000000000002056

Ejemplares similares